Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort

Yuki M F Andersen, Lea Nymand, Amy M DeLozier, Russel Burge, Emily Edson-Heredia, Alexander Egeberg

ABSTRACT

Purpose Alopecia areata (AA) is a common disorder of patchy hair loss which carries a substantial psychological burden for patients. The current understanding of AA prevalence, disease course and burden is limited, and further research is needed to improve patient care. This prospective cohort of AA patients within the Danish Skin Cohort was established to provide data that can serve as a tool in future studies of, for example, AA epidemiology and disease burden.

Participants A total of 1494 patients with dermatologist-verified AA were included in the cohort. Patients were invited and included through electronic or phone-based questionnaires. Information regarding demographics, biometrics, lifestyle factors, skin type, AA onset and development, health-related quality of life and self-reported severity assessment was collected.

Findings to date The mean (SD) age of AA onset was 32.7 (17.6) years. The mean body mass index and history of cigarette smoking was comparable with the general population. The majority (92.5%) of participants were Caucasian. In total, 72.4% of patients received their diagnosis by a physician within a year after onset of symptoms, and 66.9% reported to still have symptoms of AA within the past year. A total of 12% reported to have a first-degree family member with AA. In total, 31.4% of patients were missing all or nearly all hairs on their scalp, 32.2% had no or barely no eyelashes and 36.2% had no or barely no eyebrow hairs. Overall, most patients (55.7%) did not experience irritated eyes, but 30% reported slight eye irritation and 47.2% reported no damage to fingernails or toenails.

Future plans Observational studies regarding comorbidities, psychosocial burden of AA and efficacy of pharmacological interventions will be carried out and additional data will be linked from nationwide registries of routinely collected data. Furthermore, follow-up survey data will be added for longitudinal analyses.

INTRODUCTION

Alopecia areata (AA) is a common hair loss disorder with a life-time prevalence estimated to be approximately 2% in the USA.\textsuperscript{1,2} The condition affects both children and adults and typically presents as well-demarcated patches of hair loss in the scalp without significant visible inflammation or scarring.

AA may progress to involve the entire scalp (alopecia totalis) or all scalp and body hairs (alopecia universalis).\textsuperscript{3} The course of AA is unpredictable, and regrowth and relapse may occur, alternately. The condition is furthermore associated with atopic predispositions and various autoimmune diseases, in particular thyroid disease and vitiligo.\textsuperscript{4} The exact pathophysiology of AA is unknown, however it is considered to be a T-cell mediated autoimmune condition where hair follicles enter the telogen phase (resting phase) prematurely, resulting in hair loss.\textsuperscript{5,6}

Although AA is a common condition in dermatological practice, understanding of prevalence, prognosis and impact on patients’ lives remain scarce and the condition is understudied compared with for example, atopic dermatitis and psoriasis. A detailed description of patients with AA and establishment of a prospective cohort will enable better understanding of AA and secure an increased recognition within the field of dermatological research. Furthermore, a well-described patient cohort may serve as a tool in future research and assessment of efficacy of future emerging therapies. The aim of the current paper was to present the establishment of...
a new AA cohort within the Danish Skin Cohort and to describe patient demographics and characteristics.

**COHORT DESCRIPTION**

This study was a population-based cross-sectional study using data from the extended Danish Skin Cohort. Information regarding patient characteristics, disease onset, severity and patient-reported outcomes (PRO) were collected using questionnaires or structured interviews.

**The Danish Skin Cohort**

The Danish Skin Cohort was established in 2018 to study the prevalence, morphology and burden of skin diseases in Denmark. The cohort originally consisted of three independent samples. Sample A representing a random sample of general population adults in Denmark. Samples B and C representing groups of patients with a dermatologist verified plaque psoriasis, and atopic dermatitis, respectively. All participants in this prospective cohort were adults (> 18 years) at the time of inclusion. In 2020, the Danish Skin Cohort was expanded to also include patients with AA, hidradenitis suppurativa and rosacea. Patients with AA were identified using the Danish National Patient Registry. The registry contains information on all hospital contacts (both inpatient and outpatient) in Denmark, as well as a number of private practice dermatology clinics. Each visit is coded with a diagnostic code based on the International Classification of Diseases (ICD) system. All patients with an ICD-10 code for AA recorded in the Danish National Patient Registry at least once during adulthood (i.e., after their 18th birthday) were identified and invited to participate in the cohort. Participants were not informed that the research project was related to skin diseases until they had agreed to participate and were simply informed that the research was ‘regarding people in the Danish population’. This was to reduce the risk of participation bias. Study individuals had the opportunity to withdraw from participation on accepting the invitation, and throughout the study. A total of 3198 adults with a diagnosis of AA were invited to participate.

**Patient and public involvement**

Patients were not involved in the development of the research questions or outcome measures, but all responses to these interviews were provided by AA patients.

**Statistical analysis**

Characteristics of patients with AA were presented using summary statistics. Continuous variables with a normal distribution were presented as means and SD, while medians and IQR were presented for non-normal continuous variables. Categorical variables were presented as frequencies and percentages. As the data were purely descriptive, no test for significance was carried out.

**Patient demographics**

A total of 1494 patients with AA accepted the invitation and were included. The mean age (SD) at inclusion was 51.3 (16.0) years, with a strong female predominance of 67% (table 1). The mean age (SD) at AA onset was 32.7 (17.6) years (table 2). Previous epidemiological studies have shown contradicting results regarding the gender distribution among AA patients, where some studies show an equal distribution, while others show a greater representation of either sexes. The gender distribution may vary according to study population and study design. Our observation may partially reflect a higher awareness of hair loss among women. Furthermore, the skewed distribution may represent different response rates in different demographic groups, where middle-aged women tend to have higher response rates than young men, for example. The reported age of AA onset in our cohort is similar to previous reports, where the majority of patients tend to experience first onset of AA before the age of 40. A literature review has estimated that the mean age of onset of
Almost half of the patients had never smoked (47.1%), while 34.0% and 19.0% were former and current smokers, respectively. Furthermore, 54.7% rated themselves to having a moderate physical activity level, while 24.3% and 1.3% reported a vigorous and athletic physical activity level, respectively. Finally, 19.7% reported a sedentary lifestyle.

In comparison, patients from the Danish Skin Cohort with psoriasis have a slightly higher mean (SD) BMI of 27.5 (6.5), while patients with atopic dermatitis have a similar mean (SD) BMI of 25.9 (5.6) (data on file). The prevalence of cigarette smoking in patients with AA was comparable with the general population and lower than in patients with psoriasis in the Danish Skin Cohort. The psychological stress of having AA may influence patients’ smoking habits, however the low mean age at onset could explain why AA patients resemble the general population. Traditionally, AA is not considered a disease associated with obesity and lifestyle-related risk factors like, for example, patients with psoriasis. The current evidence on the cardiovascular risk in patients with AA is limited and
studies show conflicting results.13–15 Cigarette smoking was found to be associated with an increased risk of AA in a recent cohort study from Taiwan, however further studies are needed to establish a relationship.16

**Fitzpatrick skin type**

We found that the majority (92.5%) of patients with AA in our cohort reported a Fitzpatrick skin type 1, 2 or 3. Only 6.5% and 1.0%, respectively, reported a skin type 4 and 5. To the best of our knowledge, no data on skin type distribution is published on the Danish general population, therefore we lack a comparison group for this outcome.

Racial disparities seem to exist in the prevalence of AA, and recent US epidemiologic studies have reported that African Americans have a higher odds of AA, while Asians have a lower odds of AA compared with Caucasians.17 18 Furthermore, differences in disease prevalence according to geographical location and ethnicity is well described in autoimmune diseases such as lupus erythematosus, rheumatoid arthritis and multiple sclerosis.19 20 The Danish population is considered to be primarily Caucasian, thus not representative for investigating this characteristic of AA.

**Dermatology Life Quality Index**

Patients with AA in our cohort reported a mean (SD) DLQI of 2.1 (3.7) and median (IQR) DLQI of 1 (0–2). DLQI is a broadly used and validated outcome to measure the impact of dermatological diseases on patients’ quality of life. The score ranges from 0 to 30, where a high score signifies a high impact on health-related quality of life. We found a remarkably low DLQI in our AA cohort. One reason could be that while patients with active progressive disease may be highly affected, patients with a steady state may be less affected by AA at the time of the questionnaire. Furthermore, the DLQI system is not designed specifically for AA, and therefore some of the questions for example, regarding itching, pain and physical activities are not suitable for assessing the impact of AA. Arguably, DLQI is an inappropriate measure to thoroughly assess quality of life related to AA, since it predominantly refers to cutaneous symptoms rather than symptoms associated with hair loss.

Although AA is neither life-threatening nor necessarily accompanied by physical pain, the condition may have a significant impact on patients’ quality of life. A systematic review and meta-analysis summarised that the mean pooled DLQI score of patients with AA in three studies was 6.3 (95% CI 5.6 to 7.1).21 Interestingly, a dose–response relationship between severity of AA and health-related quality of life is uncertain,21 possibly indicating that a small patch of hair loss may be just as impactful as a larger area of hair loss. Patients with AA may carry a significant psychological burden due to the visible loss of hair and the unpredictable disease course, which in turn may cause symptoms such as anxiety, depression, stress and sleep deprivation.22 23 Hair loss may also carry a stigma relating to other forms of illnesses and oncologic chemotherapy.

**AA-specific patient-reported outcomes**

PROs related specifically to AA included information about eye irritation, missing eyelashes, missing eyebrows, damaged nails and missing scalp hair. Overall, most patients in our cohort did not experience irritated eyes (55.7%), however nearly 30% reported slight eye irritation, 10.3% and 4.8% had moderate and severe eye irritation, respectively (table 3). Most patients either reported having full eyelashes (43.6%) or no/barely no eyelashes (32.2%) on each eyelid, and full eyebrows (37.3%) or no/barely no eyebrow hairs (36.2%). When rating the finger nails or toenails most patients (47.2%) answered that the nails were not at all damaged (table 3). Notably however, most people (31.4%) were missing nearly all or all scalp hair (95%–100% of the scalp is missing hair), suggesting that a high proportion of patients had severe scalp disease.

**AA diagnosis**

The mean (SD) time from onset of symptoms to diagnosis at a general practitioner (GP) was 1.0 (3.4) years (table 2). The majority of patients (72.4%) reported that less than a year had passed from the first symptoms of AA until a diagnosis by the GP, while 17.9% and 9.7% reported more than 1 and 2 years delay, respectively. More than half of the patients (66.9%) reported that they had symptoms of AA within the past 12 months. The mean (SD) current self-reported degree of AA was 7.4 (3.2) and the median (IQR) was 9 (5–10) on a NRS from 0 to 10.

GPs in Denmark are not trained in using methods such as trichoscopy, and to prevent misclassification of individuals with other forms of hair-loss, all patients included in our cohort had to be diagnosed with AA by a dermatologist. The relatively short time interval from onset of symptoms to contact with a GP indicates an urgency and need for diagnosis and intervention for patients with AA. Interestingly, the self-reported degree of AA was rather high (median 9), while on the other hand 46.9% of the patients reported that they were only missing 0%–20% of scalp hair. This observation suggests that the subjective burden of AA may not directly correlate with objective measures.

**Family history of AA**

When asked about history of AA in the family, approximately 5% reported that either a sibling or a parent had been diagnosed with AA. Furthermore, 4% and 3% reported that a grandparent or child had AA. A total of 179 patients (12%) had at least one first degree family member with AA. An increased incidence of AA in first-degree family members have previously been reported in up to 42% of patients. Furthermore, observational studies, twin studies and genome-wide association studies suggest a strong genetic component in pathogenesis of AA, similar to other autoimmune diseases.24 25 The family
Table 3  AA-specific patient-reported outcomes

<table>
<thead>
<tr>
<th>Alopecia areata</th>
<th>n=1494</th>
</tr>
</thead>
<tbody>
<tr>
<td>(PRO measure for eye irritation) Please rate how irritated (eg, itching, stinging, burning or dry) either of your eyes have been in the past 7 days, n(%)</td>
<td></td>
</tr>
<tr>
<td>My eyes have not been irritated</td>
<td>828 (55.65)</td>
</tr>
<tr>
<td>My eyes have been a little irritated</td>
<td>436 (29.30)</td>
</tr>
<tr>
<td>My eyes have been moderately irritated</td>
<td>153 (10.28)</td>
</tr>
<tr>
<td>My eyes have been severely irritated</td>
<td>71 (4.77)</td>
</tr>
<tr>
<td>(PRO measure for eyelashes) Look at your upper and lower eyelashes on both your eyes. Please rate your eyelashes, as they look today, n(%)</td>
<td></td>
</tr>
<tr>
<td>I have full eyelashes on each eyelid</td>
<td>481 (43.61)</td>
</tr>
<tr>
<td>I have a minimal gap or minimal gaps along the eyelids</td>
<td>203 (18.40)</td>
</tr>
<tr>
<td>I have a large gap or large gaps along the eyelids</td>
<td>64 (5.80)</td>
</tr>
<tr>
<td>I have no or barely any eyelash hair</td>
<td>355 (32.18)</td>
</tr>
<tr>
<td>(PRO measure for eyebrows) Look at the hair in both of your eyebrows. Please rate your eyebrows, as they look today, n (%)</td>
<td></td>
</tr>
<tr>
<td>I have full eyebrows on each eye</td>
<td>412 (37.25)</td>
</tr>
<tr>
<td>I have a minimal gap(s) or a minimal amount of thinning in at least one of my eyebrows</td>
<td>180 (16.27)</td>
</tr>
<tr>
<td>I have a large gap(s) or a large amount of thinning in at least one of my eyebrows</td>
<td>114 (10.31)</td>
</tr>
<tr>
<td>I have no or barely any eyebrow hairs</td>
<td>400 (36.17)</td>
</tr>
<tr>
<td>(PRO measure for nail appearance) Examine your fingernails and toenails. Please rate your fingernails and toenails, as they look today, n (%)</td>
<td></td>
</tr>
<tr>
<td>Nails are not all damaged (eg, pitted, rough, brittle, split)</td>
<td>522 (47.24)</td>
</tr>
<tr>
<td>At least one nail is a little damaged (eg, pitted, rough, brittle, split)</td>
<td>303 (27.42)</td>
</tr>
<tr>
<td>At least one nail is moderately damaged (eg, pitted, rough, brittle, split)</td>
<td>193 (17.47)</td>
</tr>
<tr>
<td>At least one nail is very damaged (eg, pitted, rough, brittle, split) or you have lost at least one nail</td>
<td>87 (7.87)</td>
</tr>
<tr>
<td>(Scalp hair assessment PRO) Use mirrors to look at your entire scalp. Please rate the total area of your scalp that is missing hair right now, n (%)</td>
<td></td>
</tr>
<tr>
<td>No missing hair (0% of my scalp is missing hair; I have a full head of hair)</td>
<td>234 (15.96)</td>
</tr>
<tr>
<td>A limited area (1%–20% of my scalp is missing hair)</td>
<td>284 (16.38)</td>
</tr>
<tr>
<td>A moderate area (21%–49% of my scalp is missing hair)</td>
<td>132 (11.93)</td>
</tr>
<tr>
<td>A large area (50%–94% of my scalp is missing hair)</td>
<td>109 (9.86)</td>
</tr>
<tr>
<td>Nearly all or all (95%–100% of my scalp is missing hair)</td>
<td>347 (31.37)</td>
</tr>
</tbody>
</table>

AA, alopecia areata; PRO, patient-reported outcome.

history of AA may be underestimated in our cohort, as the condition is considered medically benign and patients with mild and/or transient symptoms may not have discussed it with their family members.

**STRENGTHS AND LIMITATIONS**

The AA extension in the Danish Skin Cohort represents a large group of patients with AA and provides an opportunity to investigate a range of variables and PROs longitudinally. The data may also be linked with routinely collected healthcare data from the nationwide Danish registries and gives us a unique opportunity to combine information on clinical manifestations of AA with pharmacological, sociodemographic data on individual-level. Patients were not interviewed about comorbidities, since information on comorbidities can be obtained on individual-level by linking patients questionnaire responses with our nationwide registries in Denmark. As with all questionnaire-based studies, this cohort carries a risk of recall bias, however the majority of patients had symptoms within the past 12 months of participation, increasing the chance of a more accurate recollection. We expect a low risk of misclassification of patients, as all participants have been diagnosed by a dermatologist. We sought to reduce the risk of participation bias by not informing about the content of the project before accepting to participate, however it is likely that some demographic groups are better represented than others, resulting in a skewed gender and/or age distribution. The overall response rate was 46.7%, which is in the normal range for surveys in Denmark. The DLQI data must be interpreted with caution, as the questionnaire is designed for 1 week recall period and some questions are more suitable for other skin conditions such as psoriasis rather than AA. Furthermore, data concerning Fitzpatrick skin type may not be extrapolated to countries with other ethnic compositions.

**COLLABORATION**

The AA cohort was established to bring new insight in disease characteristics as well as the impact of AA on different aspects of life including social, occupational and psychological behaviour. By adding longitudinal follow-up data, we hope to describe the disease trajectory and prognosis of AA, as well as explore the burden of disease over time. Furthermore, by adding routinely collected data, we will be able to investigate comorbidities and efficacy of pharmacological interventions. A deepened and more holistic understanding of AA will hopefully increase awareness of the disorder and facilitate personalised treatment strategies. Future collaboration projects with other research groups are of interest, especially collaborations where study results may be replicated in other cohorts internationally.

**Contributors** YMF, LN, AMD, RB, EE-H: conception and design, planning, interpretation of data and reporting of the work. AE: conception, design, planning,
conduct, acquisition, analysis and interpretation of data, reporting of the work. AE acts as the guarantor.

**Funding** Development of this manuscript was supported by Eli Lilly and Company.

**Competing interests** Dr YMF has received research funding from Kgl Hofbundtmager Aage Bang Foundation and AP Møller Foundation. Ms. LN has nothing to declare. Dr RTB, Mrs. AMD and Mrs. EE-H are employees and stockholders of Eli Lilly and Company. Dr AE has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis, Ltd, Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb and Janssen Pharmaceuticals.

**Patient consent for publication** Not required.

**Ethics approval** This study involves human participants but was not approved. Review of an ethics committee is not required in Denmark for studies not involving human tissue. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. There are no plans on sharing the raw data, however, data from the Danish Skin Cohort will be available for research collaborations upon obtaining the necessary legal approvals.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**ORCID iD** Alexander Egeberg http://orcid.org/0000-0001-8257-1816

**REFERENCES**